VB4-845 is a recombinant
immunotoxin that is comprised of a truncated form of Pseudomonas
exotoxin A (ETA) genetically-linked to a humanized scFv fragment, (4D5MOCB), specific to
epithelial cell adhesion molecule (
EpCAM).
EpCAM is overexpressed on a wide variety of human
tumors and thus represents a suitable target
antigen for
immunotoxin therapy. Preclinical studies were used to evaluate the benefit of locoregional administration of an ETA-based
immunotoxin versus systemic delivery. Repeated subcutaneous (s.c.) administration of
VB4-845 (up to 77.8 microg/kg) in rats resulted in minimal adverse effects, except for
injection-site reactions, while repeated systemic administration elicited symptoms consistent with vascular leak syndrome. S.c. weekly doses of the
drug in cynomolgus monkeys resulted in minimal adverse effects limited to
injection-site reactions and a transient elevation of liver
enzymes in 1 animal. Toxicokinetics showed rapid clearance of the
drug, with the development of an immune response by day 14 following repeated
injections. These results argue that the local administration of
VB4-845 has advantages with respect to safety over systemic administration and may be an effective alternative method for targeting those
cancers that are amenable to local routes of administration.